Opinion

Video

Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

Related Videos
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
John M. Burke, MD
Andrew Kuykendall, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Related Content
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine
December 10th 2024

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/8

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Chronic Lymphocytic Leukemia | © LAZLO- stock.adobe.com
December 10th 2024

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 10th 2024

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL